Company news

Share this article:
Some AstraZeneca oncology sales force personnel will be shifted to other product lines in anticipation of patent expirations. Arimidex, used for the treatment of breast cancer, will be going off patent in 2010, and Casodex, for prostate cancer, is scheduled to go off patent in 2009. A company spokesperson said while most of the oncology sales reps will be reassigned, some will be let go through attrition.
 
Wyeth has entered into acquisition talks with Crucell, a Dutch vaccine manufacturer, according to a Wall Street Journal report. Wyeth may offer as much as $1.35 billion, the report said. Crucell manufactures vaccines for hepatitis B, influenza, typhoid and cholera. 
 
Reuters reported that Icelandic company Actavis, one of the world's top generic drug manufacturers, will be auctioned off by its private-equity owners. The auction could raise as much as $6 billion or more, according to the Reuters report.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.